PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32755608-4	2020	Oral administration of the beta3-AR agonist mirabegron only elicited increases in BAT thermogenesis when ingested at the maximal allowable dose.	mirabegron	44-54	adenosine A3 receptor	Homo sapiens	27-35
32813332-1	2020	The beta3 -adrenoceptor agonist mirabegron is approved for use for overactive bladder and has been purported to be useful in the treatment of obesity-related metabolic diseases in humans, including those involving disturbances of glucose homeostasis.	mirabegron	32-42	adrenoceptor beta 3	Homo sapiens	4-23
33675781-8	2021	The present study demonstrated that the combined administration of KPR-5714 and mirabegron or tolterodine tartrate showed the additive effects on bladder dysfunction in different animal models, suggesting that the combination therapy of TRPM8 antagonist and beta3-adrenoceptor agonist or anticholinergic agent can be the potential treatment option for obtaining additive effects in comparison with monotherapy for OAB.	mirabegron	80-90	transient receptor potential cation channel, subfamily M, member 8	Rattus norvegicus	237-242
33675781-8	2021	The present study demonstrated that the combined administration of KPR-5714 and mirabegron or tolterodine tartrate showed the additive effects on bladder dysfunction in different animal models, suggesting that the combination therapy of TRPM8 antagonist and beta3-adrenoceptor agonist or anticholinergic agent can be the potential treatment option for obtaining additive effects in comparison with monotherapy for OAB.	mirabegron	80-90	adrenoceptor beta 3	Rattus norvegicus	258-276
33460524-0	2021	Body-weight-independent glucose-lowering effect of the beta3-adrenergic receptor agonist mirabegron in humans.	mirabegron	89-99	adrenoceptor beta 3	Homo sapiens	55-80
31427184-10	2019	RESULTS: In vivo application of the beta3-adrenergic receptor agonist mirabegron in humanized mice induced thermogenesis and improved the Treg induction capacity of naive T cells isolated from these animals.	mirabegron	70-80	adrenergic receptor, beta 3	Mus musculus	36-61
32030913-5	2020	Rats were pretreated with either a combination of the muscarinic antagonist tolterodine and beta3 -selective adrenoceptor agonist mirabegron or saline for 10 days.	mirabegron	130-140	UDP glucuronosyltransferase family 1 member A8	Rattus norvegicus	92-97
31961826-2	2020	Encouraging preclinical results suggest that beta3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adipose tissue (WAT) lipolysis, and insulin sensitivity.METHODSWe treated 14 healthy women of diverse ethnicities (27.5 +- 1.1 years of age, BMI of 25.4 +- 1.2 kg/m2) with 100 mg mirabegron (Myrbetriq extended-release tablet, Astellas Pharma) for 4 weeks in an open-label study.	mirabegron	369-378	adenosine A3 receptor	Homo sapiens	45-53
31961826-8	2020	Finally, an intravenous glucose tolerance test revealed higher insulin sensitivity, glucose effectiveness, and insulin secretion.CONCLUSIONThese findings indicate that human BAT metabolic activity can be increased after chronic pharmacological stimulation with mirabegron and support the investigation of beta3-AR agonists as a treatment for metabolic disease.TRIAL REGISTRATIONClinicaltrials.gov NCT03049462.FUNDINGThis work was supported by grants from the Intramural Research Program of the NIDDK, NIH (DK075112, DK075116, DK071013, and DK071014).	mirabegron	261-271	insulin	Homo sapiens	63-70
31961826-8	2020	Finally, an intravenous glucose tolerance test revealed higher insulin sensitivity, glucose effectiveness, and insulin secretion.CONCLUSIONThese findings indicate that human BAT metabolic activity can be increased after chronic pharmacological stimulation with mirabegron and support the investigation of beta3-AR agonists as a treatment for metabolic disease.TRIAL REGISTRATIONClinicaltrials.gov NCT03049462.FUNDINGThis work was supported by grants from the Intramural Research Program of the NIDDK, NIH (DK075112, DK075116, DK071013, and DK071014).	mirabegron	261-271	insulin	Homo sapiens	111-118
31961826-8	2020	Finally, an intravenous glucose tolerance test revealed higher insulin sensitivity, glucose effectiveness, and insulin secretion.CONCLUSIONThese findings indicate that human BAT metabolic activity can be increased after chronic pharmacological stimulation with mirabegron and support the investigation of beta3-AR agonists as a treatment for metabolic disease.TRIAL REGISTRATIONClinicaltrials.gov NCT03049462.FUNDINGThis work was supported by grants from the Intramural Research Program of the NIDDK, NIH (DK075112, DK075116, DK071013, and DK071014).	mirabegron	261-271	adenosine A3 receptor	Homo sapiens	305-313
31090092-6	2019	The predicted versus observed geometric mean ratio (GMR) of AUCinf for CYP2D6 substrates desipramine and metoprolol coadministered with mirabegron 100 or 160 mg once daily were 3.47 versus 3.41 and 2.97 versus 3.29, respectively, indicating that the mirabegron model can be used to predict clinical CYP2D6 inhibition.	mirabegron	136-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	71-77
31090092-6	2019	The predicted versus observed geometric mean ratio (GMR) of AUCinf for CYP2D6 substrates desipramine and metoprolol coadministered with mirabegron 100 or 160 mg once daily were 3.47 versus 3.41 and 2.97 versus 3.29, respectively, indicating that the mirabegron model can be used to predict clinical CYP2D6 inhibition.	mirabegron	136-146	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	299-305
23818156-1	2013	Mirabegron (YM178, Myrbetriq , Betanis( ), Betmiga ) is a beta3-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome.	mirabegron	12-17	adrenoceptor beta 3	Homo sapiens	58-83
31085638-5	2019	In apolipoprotein E-/- (ApoE -/-) and low-density lipoprotein (LDL) receptor-/- (Ldlr -/-) mice, oral administration of clinically relevant doses of mirabegron markedly accelerates atherosclerotic plaque growth and instability by a mechanism of increasing plasma levels of both LDL-cholesterol and very LDL-cholesterol remnants.	mirabegron	149-159	apolipoprotein E	Mus musculus	3-19
31085638-5	2019	In apolipoprotein E-/- (ApoE -/-) and low-density lipoprotein (LDL) receptor-/- (Ldlr -/-) mice, oral administration of clinically relevant doses of mirabegron markedly accelerates atherosclerotic plaque growth and instability by a mechanism of increasing plasma levels of both LDL-cholesterol and very LDL-cholesterol remnants.	mirabegron	149-159	low density lipoprotein receptor	Mus musculus	38-76
25956403-3	2015	Concentration-response curves of isoprenaline and mirabegron-induced bladder relaxation were generated against passive tension and KCl- and carbachol-induced tone, in the absence or presence of the BKCa channel inhibitor iberiotoxin (100 nM) or the Rho-kinase inhibitor Y27,632 (1 muM).	mirabegron	50-60	latexin	Homo sapiens	281-284
23818156-1	2013	Mirabegron (YM178, Myrbetriq , Betanis( ), Betmiga ) is a beta3-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome.	mirabegron	31-38	adrenoceptor beta 3	Homo sapiens	58-83
23818156-1	2013	Mirabegron (YM178, Myrbetriq , Betanis( ), Betmiga ) is a beta3-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome.	mirabegron	43-50	adrenoceptor beta 3	Homo sapiens	58-83
34314699-2	2021	Here, we report the cryogenic electron microscopy structure of the beta3AR-Gs signaling complex with the selective agonist mirabegron, a first-in-class drug for OAB.	mirabegron	123-133	adenosine A3 receptor	Homo sapiens	67-74
17293563-2	2007	YM178 increased cyclic AMP accumulation in Chinese hamster ovary (CHO) cells expressing human beta3-adrenoceptor (AR).	mirabegron	0-5	adrenoceptor beta 3	Homo sapiens	94-112
17293563-2	2007	YM178 increased cyclic AMP accumulation in Chinese hamster ovary (CHO) cells expressing human beta3-adrenoceptor (AR).	mirabegron	0-5	adrenoceptor beta 3	Homo sapiens	114-116
17293563-4	2007	EC50 values of YM178 for human beta1- and beta2-ARs were 10,000 nM or more, respectively.	mirabegron	15-20	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	31-47
17293563-5	2007	The ratio of intrinsic activities of YM178 versus maximal response induced by isoproterenol (nonselective beta-AR agonist) was 0.8 for human beta3-ARs, 0.1 for human beta1-ARs, and 0.1 for human beta2-ARs.	mirabegron	37-42	eukaryotic translation elongation factor 1 beta 2 pseudogene 2	Homo sapiens	141-146
35247188-7	2022	BAT is clearly stimulated in individuals exposed to cold or treated with high doses of the beta3-adrenergic agonist mirabegron, whereas browning is certainly induced in patients after burn injury or with pheochromocytoma, as well as in individuals treated with beta3-adrenergic agonist mirabegron for at least 10 weeks.	mirabegron	116-126	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	91-96
34152510-7	2021	Furthermore, treatment with mirabegron (10mg/kg per day by oral administration for 6 weeks) ameliorated atherosclerosis in ApoE-/- mice in CIH but not in normoxia.	mirabegron	28-38	apolipoprotein E	Mus musculus	123-127
34152510-10	2021	CONCLUSION: This study first demonstrated that mirabegron impeded the progression of CIH-induced atherosclerosis, at least in part, via beta3 AR-mediated oxidative stress, suggesting a promising therapeutic strategy for protecting against atherosclerosis induced by CIH.	mirabegron	47-57	adenosine A3 receptor	Homo sapiens	136-144
35247188-7	2022	BAT is clearly stimulated in individuals exposed to cold or treated with high doses of the beta3-adrenergic agonist mirabegron, whereas browning is certainly induced in patients after burn injury or with pheochromocytoma, as well as in individuals treated with beta3-adrenergic agonist mirabegron for at least 10 weeks.	mirabegron	116-126	T cell immune regulator 1, ATPase H+ transporting V0 subunit a3	Homo sapiens	261-266
35216317-10	2022	The DOXO-induced overexpression of Il1 and Il6 was markedly decreased by losartan and mirabegron.	mirabegron	86-96	interleukin 6	Rattus norvegicus	43-46